Vaccine adjuvants are compounds that are commonly used as immune stimulating additives in vaccines. They enhance the immune response of the antigen and help generate greater immune response to vaccines, which allows for weaker antigens or lower doses of vaccines, thereby increasing the vaccine production capacity. Adjuvants can also reduce the frequency of administration of vaccine booster shots or the amount of antigen required in each dose. The global vaccine adjuvant market is primarily driven by the increasing awareness and initiatives towards preventive healthcare.
The global Vaccine Adjuvant Market was valued at US$ 1,430.0 Mn in 2021 and is forecast to reach a value of US$ 3,521.5 Mn by 2028 at a CAGR of 13.7% between 2022 and 2028.
Key Takeaways
Key players operating in the Vaccine Adjuvant market are Thermo Fisher Scientific Inc., Air Liquide (Seppic), Pacific GeneTech Limited, OZ Biosciences, Novavax Inc., Merck & Co. Inc., InvivoGen, GlaxoSmithKline PLC, Dynavax Technologies Corporation, CSL Limited, Croda International PLC, Vertellus, Aphios Corporation, Agenus Inc., Adjuvatis, and Associated British Foods PLC (SPI Pharma Inc.), among others. GSK leads the market with its MPL and AS adjuvant technologies in various vaccines.
Vaccine Adjuvant Market Demand is driven by the growing need to combat infectious diseases globally. Innovations in adjuvant formulation and immune response mechanisms are enabling the development of next-generation adjuvants to enhance vaccine efficacy.
Market Trends
Increasing partnerships and collaborations between adjuvant manufacturers and vaccine developers: Manufacturers are collaborating with vaccine companies to develop and supply adjuvants formulated specifically for certain vaccines.
Growing focus on vaccine thermostability: Efforts are underway to develop thermostable adjuvants that can improve stability of vaccines at varied temperatures without refrigeration, facilitating easy transport and storage in tropical regions.
Market Opportunities
Strong pipeline of vaccines for infectious diseases, cancer, and other therapeutic applications present an ongoing need for safe and effective adjuvants.Development of novel adjuvant formulations tailored for pediatric vaccines, malaria vaccines, COVID-19 vaccines and therapeutic vaccines presents major opportunities.
Impact of COVID-19 on Vaccine Adjuvant market growth
The COVID-19 pandemic significantly impacted the growth of the vaccine adjuvant market. Vaccine manufacturers faced supply chain disruptions and delays in clinical trials due to lockdowns and social distancing measures imposed globally. Research activities slowed down considerably during the early phases of the pandemic. However, with the development of COVID-19 vaccines, the demand and research for vaccine adjuvants picked up pace. Vaccine adjuvants help vaccines produce enhanced immun response and longer lasting immunity against the virus. Their use allows greater antigen sparing, which helps vaccine manufacturers produce more doses of the vaccine. Several COVID-19 vaccines used novel adjuvant systems like oil-in-water adjuvants to boost their immune response. The pandemic highlighted the critical role played by adjuvants in developing effective and widely available vaccines during a health crisis. With increased focus on pandemic preparedness, funding for adjuvant research is expected to rise substantially in the coming years.
Geographical regions with high Vaccine Adjuvant
North America currently dominates the global vaccine adjuvant market in terms of revenue owing to large pharmaceutical companies, rising R&D investments and growing adoption of newer vaccine technologies. The US constitutes a major share of the North America market. Europe holds the second position supported by increasing government focus on immunotherapy and adjuvant research. Countries like the UK, Germany, and France are major European markets. Asia Pacific is expected to be the fastest growing region for vaccine adjuvants during the forecast period. This can be attributed to improving healthcare expenditure, rising awareness about newer vaccines, and increasing government initiatives in countries like India and China.
Fastest Growing Region for Vaccine Adjuvant Market
Asia Pacific is poised to be the fastest growing region in the global vaccine adjuvant market during the forecast period. This growth can be credited to a burgeoning biotechnology industry in the region supported by government tax incentives and investments. Also, increasing burden of infectious diseases and rising demand for therapeutic vaccines in developing Asia Pacific countries will drive the adoption of vaccine adjuvants. Further, growing contract manufacturing in the region to cater to global vaccine demand will propel adjuvant production. Countries like China, India, South Korea and Japan are spearheading vaccine adjuvant research and production activities in Asia Pacific. With a large population base and improving healthcare infrastructure, the region offers immense scope for vaccine adjuvant market penetration and future growth opportunities.
Get More Insights - Vaccine Adjuvants Market
Get This Report in Japanese Language -ワクチンアジュバント市場
Get This Report in Korean Language -백신 보조제 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
copyright src="chrome-extension://fpjppnhnpnknbenelmbnidjbolhandnf/content_script_web_accessible/ecp_regular.js" type="text/javascript">